Across TCGA pan-cancer cohorts, TOR4A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TOR4A data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TOR4A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TOR4A expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where TOR4A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.145	0.774	.016	12	view →
PDAC	OS	Tertile	II,III,IV	0.573	0.270	.013	8	view →
LSCC	DFS	Tertile	II,III,IV	0.581	0.892	.028	5	view →
UCEC	DFS	Median	II,III,IV	0.536	0.880	.044	4	view →
LUAD	OS	Quartile	All	0.687	0.939	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: TOR4A tumor-vs-normal RNA expression · all TOR4A data types